
Spruce Biosciences, Inc.: financial statements
Price
$38.00
November 20, 2026Market cap $109M
What Ploutos Investor adds for Spruce Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 23% since Nov 9, 2026, when the 10-Q these figures come from was filed ($49.34 then, $38.00 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $10M | $4.9M | $0 | |
| Operating income | -$52M | -$56M | -$37M | |
| Net income | -$48M | -$53M | -$39M | |
| Earnings per share | -$1.24 | -$96.40 | -$50.83 | |
| Earnings per share, basic | -$1.24 | -$96.40 | -$50.83 | |
| Margins | ||||
| Operating margin | -515.3% | -1,143.4% | – | |
| Net margin | -475.0% | -1,079.9% | – | |
Financial statements
SPRB's revenue, profits and cash flows from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
When the debt falls due
Dec 31, 2024Due within 2 years
$1.8M
Total falling due
$1.8M
Total in the ladder $1.8M, from the annual report dated December 31, 2024. Principal of loans and bonds, without leases and interest. The filing
- 2025: $1.7M
- 2026: $136.0K
- 2027: –
- 2028: –
- 2029: –
- 2030 on: –
The ladder at each year end
| Year | 1 yr | 2 yrs | 3 yrs | 4 yrs | 5 yrs | Later |
|---|---|---|---|---|---|---|
| 2024 | $1.7M | $136.0K | – | – | – | – |
| 2023 | $1.9M | $1.7M | $136.0K | – | – | – |
| 2022 | $2.0M | $1.8M | $1.7M | $136.0K | – | – |
The ladder at each year end
When SPRB's debt fell due, as each annual report set it out, from 2020 to 2021, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Leases
Dec 31, 2025Operating leases
$736.0K
Finance leases
–
- Average discount rate
- 8.0%
- Lease cost for the year
- $337.0K
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate SPRB paid on its profit, from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
Other than debt, no claim large enough to list ranks ahead of the shares.
From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Spruce Biosciences's filings show?
These are Spruce Biosciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did SPRB have in 2025?
Spruce Biosciences had revenue of $0 and net income of -$39M in fiscal 2025, a net margin of .
How much debt does SPRB have?
On December 31, 2025 Spruce Biosciences had total assets of $53M, debt of – and shareholders' equity of $43M.
Where are the figures from?
From Spruce Biosciences, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.